( 0 1 0 1 O
transformed 1 12 1 12 O
DLBCL 13 18 13 18 B-cancer
from 19 23 19 23 O
Follicular 24 34 24 34 B-cancer
NHL 35 38 35 38 I-cancer
are 39 42 39 42 O
eligible 43 51 43 51 O
) 51 52 51 52 O

Active 0 6 53 59 B-chronic_disease
infection 7 16 60 69 I-chronic_disease
requiring 17 26 70 79 O
systemic 27 35 80 88 B-treatment
treatment 36 45 89 98 I-treatment

Bilirubin 0 9 99 108 B-clinical_variable
< 10 11 109 110 O
20.0mg 12 18 111 117 B-upper_bound
/ 18 19 117 118 I-upper_bound
dL 19 21 118 120 I-upper_bound
( 22 23 121 122 O
if 23 25 122 124 O
Gilberts 26 34 125 133 B-clinical_variable
then 35 39 134 138 O
< 40 41 139 140 O
2.5 42 45 141 144 B-upper_bound
mg 46 48 145 147 I-upper_bound
/ 48 49 147 148 I-upper_bound
dL 49 51 148 150 I-upper_bound
) 51 52 150 151 O
and 53 56 152 155 O
AST 57 60 156 159 B-clinical_variable
/ 60 61 159 160 I-clinical_variable
AST 61 64 160 163 I-clinical_variable
< 65 66 164 165 O
2.5 67 70 166 169 B-upper_bound
ULN 71 74 170 173 I-upper_bound

Burkitt 0 7 174 181 B-cancer
's 7 9 181 183 I-cancer
lymphoma 10 18 184 192 I-cancer

Burkitt 0 7 193 200 B-cancer
- 7 8 200 201 I-cancer
like 8 12 201 205 I-cancer
Lymphoma 13 21 206 214 I-cancer

Chronic 0 7 215 222 O
treatment 8 17 223 232 B-treatment
with 18 22 233 237 O
strong 23 29 238 244 O
CYP3A4 30 36 245 251 B-treatment
inhibitor/ 37 47 252 262 I-treatment
inducer 48 55 263 270 I-treatment
, 55 56 270 271 O
acid 57 61 272 276 B-treatment
reducing 62 70 277 285 I-treatment
agent 71 76 286 291 I-treatment
, 76 77 291 292 O
Proton 78 84 293 299 B-treatment
pump 85 89 300 304 I-treatment
inhibitors 90 100 305 315 I-treatment

Current 0 7 316 323 O
use 8 11 324 327 O
of 12 14 328 330 O
systemic 15 23 331 339 B-treatment
steroids 24 32 340 348 I-treatment
> 33 34 349 350 O
20 34 36 350 352 B-lower_bound
mg 37 39 353 355 I-lower_bound
QD 40 42 356 358 B-clinical_variable
prednisone 43 53 359 369 I-clinical_variable
( 54 55 370 371 O
or 55 57 371 373 O
equivalent 58 68 374 384 O
) 68 69 384 385 O

ECOG 0 4 386 390 B-clinical_variable
Score 5 10 391 396 I-clinical_variable
of 11 13 397 399 O
0 14 15 400 401 B-lower_bound
or 16 18 402 404 O
1 19 20 405 406 B-upper_bound

For 0 3 407 410 O
CTCL 4 8 411 415 B-cancer
: 8 9 415 416 O
( 10 11 417 418 O
TSEBT 11 16 418 423 B-treatment
) 16 17 423 424 O
within 18 24 425 431 O
12 25 27 432 434 B-upper_bound
weeks 28 33 435 440 I-upper_bound
, 33 34 440 441 O
or 35 37 442 444 O
initiation 38 48 445 455 O
of 49 51 456 458 O
topical 52 59 459 466 B-treatment
steroid 60 67 467 474 I-treatment
, 67 68 474 475 O
nitrogen 69 77 476 484 B-treatment
mustard 78 85 485 492 I-treatment
, 85 86 492 493 O
or 87 89 494 496 O
topical 90 97 497 504 B-treatment
retinoid 98 106 505 513 I-treatment
within 107 113 514 520 O
2 114 115 521 522 O
weeks 116 121 523 528 O
. 121 122 528 529 O
( 123 124 530 531 O
Stable 124 130 531 537 O
topical 131 138 538 545 O
≥ 139 140 546 547 O
4 141 142 548 549 B-lower_bound
weeks 143 148 550 555 I-lower_bound
prior 149 154 556 561 I-lower_bound
to 155 157 562 564 O
Day 158 161 565 568 O
1 162 163 569 570 O
allowed 164 171 571 578 O
) 171 172 578 579 O

Hematologic 0 11 580 591 B-clinical_variable
ANC 12 15 592 595 I-clinical_variable
> 16 17 596 597 O
1000 18 22 598 602 B-lower_bound
/ 22 23 602 603 I-lower_bound
uL 23 25 603 605 I-lower_bound
and 26 29 606 609 O
platelet 30 38 610 618 B-clinical_variable
> 39 40 619 620 O
75,000 41 47 621 627 B-lower_bound
/ 47 48 627 628 I-lower_bound
uL 48 50 628 630 I-lower_bound

Histological 0 12 631 643 O
evidence 13 21 644 652 O
: 21 22 652 653 O
FL 23 25 654 656 B-cancer
Grade 26 31 657 662 I-cancer
1 32 33 663 664 I-cancer
- 33 34 664 665 I-cancer
3A 34 36 665 667 I-cancer
/ 36 37 667 668 I-cancer
iNHL 37 41 668 672 I-cancer
, 41 42 672 673 O
with 43 47 674 678 O
relapsed 48 56 679 687 O
or 57 59 688 690 O
refractory 60 70 691 701 O
disease 71 78 702 709 O
( 79 80 710 711 O
iNHL 80 84 711 715 O
includes 85 93 716 724 O
LPL 94 97 725 728 B-cancer
/ 97 98 728 729 O
WM 98 100 729 731 B-cancer
, 100 101 731 732 O
MZL 102 105 733 736 B-cancer
) 105 106 736 737 O
; 106 107 737 738 O
aNHL 108 112 739 743 B-cancer
, 112 113 743 744 O
defined 114 121 745 752 O
as 122 124 753 755 O
DLBCL 125 130 756 761 B-cancer
, 130 131 761 762 O
FL 132 134 763 765 B-cancer
Grade 135 140 766 771 I-cancer
3B 141 143 772 774 I-cancer
, 143 144 774 775 O
MCL 145 148 776 779 B-cancer
, 148 149 779 780 O
and 150 153 781 784 O
transformed 154 165 785 796 O
NHL 166 169 797 800 O
with 170 174 801 805 O
relapsed 175 183 806 814 O
disease 184 191 815 822 O
; 191 192 822 823 O
CLL 193 196 824 827 B-cancer
/ 196 197 827 828 O
SLL 197 200 828 831 B-cancer
, 200 201 831 832 O
PTCL 202 206 833 837 B-cancer
, 206 207 837 838 O
or 208 210 839 841 O
CTCL 211 215 842 846 B-cancer
( 216 217 847 848 O
with 217 221 848 852 O
MF 222 224 853 855 B-cancer
/ 224 225 855 856 O
SS 225 227 856 858 B-cancer
) 227 228 858 859 O
with 229 233 860 864 O
relapsed 234 242 865 873 O
or 243 245 874 876 O
refractory 246 256 877 887 O

Known 0 5 888 893 O
carrier 6 13 894 901 O
or 14 16 902 904 O
infection 17 26 905 914 O
for 27 30 915 918 O
HIV 31 34 919 922 B-chronic_disease
/ 34 35 922 923 O
Hep 35 38 923 926 B-chronic_disease
B 39 40 927 928 I-chronic_disease
or 41 43 929 931 I-chronic_disease
C. 44 46 932 934 I-chronic_disease
HCV 47 50 935 938 B-chronic_disease
ab+ 51 54 939 942 I-chronic_disease
must 55 59 943 947 O
be 60 62 948 950 O
PCR- 63 67 951 955 O
. 67 68 955 956 O
HBV 69 72 957 960 B-chronic_disease
ab+ 73 76 961 964 I-chronic_disease
must 77 81 965 969 O
be 82 84 970 972 O
HBsAg- 85 91 973 979 O
or 92 94 980 982 O
undetectable 95 107 983 995 O
DNA 108 111 996 999 O

Known 0 5 1000 1005 O
lymphomatous 6 18 1006 1018 B-cancer
involvement 19 30 1019 1030 I-cancer
of 31 33 1031 1033 I-cancer
the 34 37 1034 1037 I-cancer
CNS 38 41 1038 1041 I-cancer

Major 0 5 1042 1047 B-treatment
surgery 6 13 1048 1055 I-treatment
within 14 20 1056 1062 O
4 21 22 1063 1064 B-upper_bound
weeks 23 28 1065 1070 I-upper_bound

Measureable 0 11 1071 1082 O
disease 12 19 1083 1090 O
defined 20 27 1091 1098 O
as 28 30 1099 1101 O
: 30 31 1101 1102 O
≥ 32 33 1103 1104 O
1 34 35 1105 1106 B-lower_bound
lesion 36 42 1107 1113 B-clinical_variable
≥ 43 44 1114 1115 O
1.5 45 48 1116 1119 B-lower_bound
cm 49 51 1120 1122 I-lower_bound
single 52 58 1123 1129 I-lower_bound
dimension 59 68 1130 1139 I-lower_bound
via 69 72 1140 1143 O
CT 73 75 1144 1146 B-treatment
, 75 76 1146 1147 O
CT 77 79 1148 1150 B-treatment
/ 79 80 1150 1151 I-treatment
PET 80 83 1151 1154 I-treatment
with 84 88 1155 1159 O
nodal 89 94 1160 1165 B-cancer
or 95 97 1166 1168 I-cancer
mass 98 102 1169 1173 I-cancer
lesions 103 110 1174 1181 I-cancer
; 110 111 1181 1182 O
Quantifiable 112 124 1183 1195 O
circulating 125 136 1196 1207 B-cancer
tumor 137 142 1208 1213 I-cancer
cells 143 148 1214 1219 I-cancer
; 148 149 1219 1220 O
or 150 152 1221 1223 O
for 153 156 1224 1227 O
Waldenström 157 168 1228 1239 B-cancer
's 168 170 1239 1241 I-cancer
macroglobulinemia 171 188 1242 1259 I-cancer
presence 189 197 1260 1268 O
of 198 200 1269 1271 O
IgM 201 204 1272 1275 B-clinical_variable
l 205 206 1276 1277 I-clinical_variable
> 207 208 1278 1279 O
2X 209 211 1280 1282 B-lower_bound
ULN 212 215 1283 1286 I-lower_bound
; 215 216 1286 1287 O
For 217 220 1288 1291 O
CTCL 221 225 1292 1296 B-cancer
: 225 226 1296 1297 O
mSWAT 227 232 1298 1303 B-clinical_variable
> 233 234 1304 1305 O
0 235 236 1306 1307 B-lower_bound

Previous 0 8 1308 1316 O
malignancies 9 21 1317 1329 B-cancer
within 22 28 1330 1336 O
2 29 30 1337 1338 B-upper_bound
yrs 31 34 1339 1342 I-upper_bound
. 34 35 1342 1343 O
unless 36 42 1344 1350 O
relapse 43 50 1351 1358 O
risk 51 55 1359 1363 O
is 56 58 1364 1366 O
small 59 64 1367 1372 O
( 65 66 1373 1374 O
< 66 67 1374 1375 O
5 68 69 1376 1377 B-upper_bound
% 69 70 1377 1378 I-upper_bound
) 70 71 1378 1379 O

Prior 0 5 1380 1385 O
monoclonal 6 16 1386 1396 O
antibody 17 25 1397 1405 O
, 25 26 1405 1406 O
radioimmunoconjugate 27 47 1407 1427 B-treatment
, 47 48 1427 1428 O
antibody 49 57 1429 1437 B-treatment
drug 58 62 1438 1442 I-treatment
conjugate 63 72 1443 1452 I-treatment
, 72 73 1452 1453 O
phototherapy 74 86 1454 1466 B-treatment
, 86 87 1466 1467 O
radiotherapy 88 100 1468 1480 B-treatment
, 100 101 1480 1481 O
chemotherapy 102 114 1482 1494 B-treatment
, 114 115 1494 1495 O
immunotherapy 116 129 1496 1509 B-treatment
, 129 130 1509 1510 O
immunosuppressive 131 148 1511 1528 B-treatment
therapy 149 156 1529 1536 I-treatment
, 156 157 1536 1537 O
or 158 160 1538 1540 O
any 161 164 1541 1544 O
test 165 169 1545 1549 O
agent 170 175 1550 1555 O
within 176 182 1556 1562 O
3 183 184 1563 1564 B-upper_bound
weeks 185 190 1565 1570 I-upper_bound
or 191 193 1571 1573 O
for 194 197 1574 1577 O
alemtuzumab 198 209 1578 1589 B-treatment
8 210 211 1590 1591 O
weeks 212 217 1592 1597 O
of 218 220 1598 1600 O
Day 221 224 1601 1604 O
1 225 226 1605 1606 O

Prior 0 5 1607 1612 B-treatment
therapy 6 13 1613 1620 I-treatment
with 14 18 1621 1625 I-treatment
SYK 19 22 1626 1629 I-treatment
inhibitors 23 33 1630 1640 I-treatment

Prior 0 5 1641 1646 B-treatment
transplant 6 16 1647 1657 I-treatment
with 17 21 1658 1662 I-treatment
stem 22 26 1663 1667 I-treatment
cell 27 31 1668 1672 I-treatment
infusion 32 40 1673 1681 I-treatment
90 41 43 1682 1684 B-upper_bound
days 44 48 1685 1689 I-upper_bound
or 49 51 1690 1692 O
active 52 58 1693 1699 B-treatment
graft 59 64 1700 1705 I-treatment
- 64 65 1705 1706 I-treatment
versus 65 71 1706 1712 I-treatment
- 71 72 1712 1713 I-treatment
host 72 76 1713 1717 I-treatment
treatment 77 86 1718 1727 I-treatment
within 87 93 1728 1734 O
8 94 95 1735 1736 B-upper_bound
weeks 96 101 1737 1742 I-upper_bound
of 102 104 1743 1745 O
Day 105 108 1746 1749 O
1 109 110 1750 1751 O

Prior 0 5 1752 1757 O
treatment 6 15 1758 1767 O
for 16 19 1768 1771 O
lymphoid 20 28 1772 1780 B-cancer
malignancy 29 39 1781 1791 I-cancer
for 40 43 1792 1795 O
progressive 44 55 1796 1807 O
/refractory 56 67 1808 1819 O
disease 68 75 1820 1827 O

Received 0 8 1828 1836 O
BCR 9 12 1837 1840 B-treatment
and/or 13 19 1841 1847 I-treatment
BCL2 20 24 1848 1852 I-treatment
inhibitors 25 35 1853 1863 I-treatment
were 36 40 1864 1868 O
intolerant 41 51 1869 1879 O
or 52 54 1880 1882 O
had 55 58 1883 1886 O
relapsed 59 67 1887 1895 O
/ 67 68 1895 1896 O
refractory 68 78 1896 1906 O
disease 79 86 1907 1914 O
afterwards 87 97 1915 1925 O

Richter 0 7 1926 1933 B-cancer
's 7 9 1933 1935 I-cancer
syndrome 10 18 1936 1944 I-cancer

Serum 0 5 1945 1950 B-clinical_variable
creatinine 6 16 1951 1961 I-clinical_variable
of 17 19 1962 1964 O
< 20 21 1965 1966 O
1.5 22 25 1967 1970 B-upper_bound
ULN 26 29 1971 1974 I-upper_bound
or 30 32 1975 1977 O
calculated 33 43 1978 1988 B-clinical_variable
CrCl 44 48 1989 1993 I-clinical_variable
of 49 51 1994 1996 O
> 52 53 1997 1998 O
50 54 56 1999 2001 B-lower_bound
mL 57 59 2002 2004 I-lower_bound
/ 59 60 2004 2005 I-lower_bound
min 60 63 2005 2008 I-lower_bound

Significant 0 11 2009 2020 O
GI 12 14 2021 2023 B-chronic_disease
disease 15 22 2024 2031 I-chronic_disease
, 22 23 2031 2032 O
previous 24 32 2033 2041 O
major 33 38 2042 2047 B-treatment
gastric 39 46 2048 2055 I-treatment
/ 46 47 2055 2056 I-treatment
bowel 47 52 2056 2061 I-treatment
surgery 53 60 2062 2069 I-treatment
, 60 61 2069 2070 O
difficulty 62 72 2071 2081 B-chronic_disease
swallowing 73 83 2082 2092 I-chronic_disease
or 84 86 2093 2095 O
malabsorption 87 100 2096 2109 B-chronic_disease
syndrome 101 109 2110 2118 I-chronic_disease

Specific 0 8 2119 2127 O
Patient 9 16 2128 2135 O
at 17 19 2136 2138 O
least 20 25 2139 2144 O
18yrs 26 31 2145 2150 B-lower_bound
of 32 34 2151 2153 O
age 35 38 2154 2157 B-age
with 39 43 2158 2162 O
histologically 44 58 2163 2177 O
confirmed 59 68 2178 2187 O
CLL 69 72 2188 2191 B-cancer
/ 72 73 2191 2192 O
SLL 73 76 2192 2195 B-cancer
or 77 79 2196 2198 O
B 80 81 2199 2200 B-cancer
- 81 82 2200 2201 I-cancer
cell 82 86 2201 2205 I-cancer
Non 87 90 2206 2209 I-cancer
- 90 91 2209 2210 I-cancer
Hodgkin 91 98 2210 2217 I-cancer
lymphoma 99 107 2218 2226 I-cancer
( 108 109 2227 2228 O
DLBCL 109 114 2228 2233 B-cancer
, 114 115 2233 2234 O
FL 116 118 2235 2237 B-cancer
, 118 119 2237 2238 O
MCL 120 123 2239 2242 B-cancer
, 123 124 2242 2243 O
MZL 125 128 2244 2247 B-cancer
, 128 129 2247 2248 O
lymphoplasmacytic 130 147 2249 2266 B-cancer
lymphoma 148 156 2267 2275 I-cancer
) 156 157 2275 2276 O

pregnant 0 8 2277 2285 B-pregnancy
( 9 10 2286 2287 O
intention 10 19 2287 2296 O
to 20 22 2297 2299 O
become 23 29 2300 2306 O
) 29 30 2306 2307 O
females 31 38 2308 2315 B-gender
or 39 41 2316 2318 O
participation 42 55 2319 2332 O
in 56 58 2333 2335 O
other 59 64 2336 2341 B-treatment
clinical 65 73 2342 2350 I-treatment
trials 74 80 2351 2357 I-treatment

previous 0 8 2358 2366 O
drug 9 13 2367 2371 O
- 13 14 2371 2372 O
related 14 21 2372 2379 O
toxicity 22 30 2380 2388 O
( 31 32 2389 2390 O
except 32 38 2390 2396 O
alopecia 39 47 2397 2405 B-chronic_disease
, 47 48 2405 2406 O
erectile 49 57 2407 2415 B-chronic_disease
impotence 58 67 2416 2425 I-chronic_disease
, 67 68 2425 2426 O
hot 69 72 2427 2430 O
flashes 73 80 2431 2438 O
, 80 81 2438 2439 O
libido 82 88 2440 2446 O
, 88 89 2446 2447 O
neuropathy 90 100 2448 2458 B-chronic_disease
) 100 101 2458 2459 O

≥ 0 1 2460 2461 O
1 2 3 2462 2463 B-lower_bound
prior 4 9 2464 2469 B-treatment
regimen 10 17 2470 2477 I-treatment
( 18 19 2478 2479 O
min 19 22 2479 2482 O
2 23 24 2483 2484 B-lower_bound
cycles 25 31 2485 2491 O
) 31 32 2491 2492 O
with 33 37 2493 2497 O
antibody 38 46 2498 2506 B-treatment
conjugate 47 56 2507 2516 I-treatment
, 56 57 2516 2517 O
cytotoxic 58 67 2518 2527 B-treatment
chemotherapy 68 80 2528 2540 I-treatment
, 80 81 2540 2541 O
or 82 84 2542 2544 O
TKI 85 88 2545 2548 B-treatment
alone 89 94 2549 2554 O
or 95 97 2555 2557 O
in 98 100 2558 2560 O
combination 101 112 2561 2572 O

